Nillius S J, Bergquist C, Wide L
Contraception. 1978 Jun;17(6):537-45.
A stimulatory luteinizing hormone-releasing hormone (LRH) analogue D-Ser(TBU)6-EA10-LRH was administered subcutaneously once daily in a dose of 5 microgram to four regularly menstruating women. Treatment was instituted within the first three days of the menstrual bleeding and continued for 22--30 days. Ovulation was inhibited in all the women during the treatment cycle. The treatment resulted in disturbances in the pituitary gonadotropin secretion which presumably led to disordered follicular menuration and anovulation. The maximum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) responses to the LRH analogue were obtained during the first few days of treatment. The gonadotropin responses then rapidly decreased during the prolonged treatment. This change in the pituitary responsiveness probably prevented the release of a normal preovulatory LH surge. After the treatment, all the women resumed normal ovulatory menstrual cycles. The results suggest that it might be possible to use stimulatory LRH analogues for birth control.
向四名月经周期正常的女性皮下注射一种促性腺激素释放激素(LRH)类似物D-Ser(TBU)6-EA10-LRH,剂量为每日5微克,每日一次。在月经出血的头三天内开始治疗,并持续22至30天。在治疗周期中,所有女性的排卵均受到抑制。该治疗导致垂体促性腺激素分泌紊乱,这可能导致卵泡月经紊乱和无排卵。在治疗的最初几天内,促卵泡生成素(FSH)和促黄体生成素(LH)对LRH类似物的反应达到最大值。在延长治疗期间,促性腺激素反应迅速下降。垂体反应性的这种变化可能阻止了正常排卵前LH峰的释放。治疗后,所有女性都恢复了正常的排卵月经周期。结果表明,使用促性腺激素释放激素类似物进行避孕可能是可行的。